Actuate Therapeutics (ACTU) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 1, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: $0No open-market trades
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, latest quarter: NoneNo large changes

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about ACTU filings

Are insiders buying or selling Actuate Therapeutics, Inc. Common stock (ACTU) stock?

Neither. Actuate Therapeutics, Inc. Common stock (ACTU) insiders filed no open-market purchases or sales in the 90 days to Nov 1, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ACTU recently?

None. No member of Congress disclosed a ACTU trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ACTU smart-money data?

This summary uses filings available on Nov 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

9 funds hold a position and insiders have been net buying.

Questions about ACTU filings

Are insiders buying or selling Actuate Therapeutics, Inc. Common stock (ACTU) stock?

Neither. Actuate Therapeutics, Inc. Common stock (ACTU) insiders filed no open-market purchases or sales in the 90 days to Nov 1, 2026, according to SEC Form 4 filings.

Which members of Congress have traded ACTU recently?

None. No member of Congress disclosed a ACTU trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this ACTU smart-money data?

Insiders

What insiders are doing

1 trade · 6 mo

Buys (1)

SD
Schmitt Daniel M
President, CEO and Director · Oct 29
$50K
private deal

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 13, 2026

Earnings came in 4.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 13, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.20+4.76% beat

-$0.21 expected

Revenue

Unavailable

Revenue data unavailable

Next report

Estimated report: Nov 12, 2026, in 11 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 13, 2026	-$0.20est. -$0.21	+4.76%beat	Not on file	Not on file
Mar 31, 2026Reported May 14, 2026	-$0.24est. -$0.21	-14.29%miss	Not on file	Not on file
Dec 31, 2025Reported Mar 26, 2026	-$0.18est. -$0.24	+25.00%beat	Not on file	Not on file
Sep 30, 2025Reported Nov 13, 2025	-$0.25est. -$0.28	+10.71%beat	Not on file	Not on file
Jun 30, 2025Reported Aug 14, 2025	-$0.30est. -$0.31	+3.23%beat	Not on file	Not on file
Mar 31, 2025Reported May 15, 2025	-$0.32est. -$0.26	-23.08%miss	Not on file	Not on file
Dec 31, 2024Reported Mar 13, 2025	-$0.33est. -$0.29	-13.79%miss	Not on file	Not on file
Sep 30, 2024Reported Nov 13, 2024	-$0.55Reported	No estimate	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $0.38
52-wk high: $7.90
High: $0.42
52-wk low: $0.33
Low: $0.36
Prev close: $0.38
Mkt cap: $18.4M
ROE: -554.0%
Beta: 1.20
P/B: 9.1x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $18M

Valuation

P/B9.10

Quality

Operating margin0.0%
ROE-554.0%
ROA-213.4%

Growth

Beta1.20

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

35balanced

20D volatility

196%annualized

52-week range

$0.37

$0.33$7.90

20D support

$0.35recent floor

20D resistance

$0.95recent ceiling

Returns

5D -28.1%20D -58.3%60D -67.2%

Price vs moving averages

SMA20 -36.1%SMA50 -59.6%SMA200 -83.0%

Volume pace

1.75xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Jun 30, 2026Aug 13, 2026

-$0.20est. -$0.21

+4.76%

Not on file

Mar 31, 2026May 14, 2026

-$0.24est. -$0.21

-14.29%

Not on file

Dec 31, 2025Mar 26, 2026

-$0.18est. -$0.24

+25.00%

Not on file

Sep 30, 2025Nov 13, 2025

-$0.25est. -$0.28

+10.71%

Not on file

Jun 30, 2025Aug 14, 2025

-$0.30est. -$0.31

+3.23%

Not on file

Mar 31, 2025May 15, 2025

-$0.32est. -$0.26

-23.08%

Not on file

Dec 31, 2024Mar 13, 2025

-$0.33est. -$0.29

-13.79%

Not on file

Sep 30, 2024Nov 13, 2024

-$0.55Reported

No estimate

Not on file

Actuate Therapeutics, Inc. Common stock

Smart money at a glance

What do analysts expect?

Questions about ACTU filings

Questions about ACTU filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 4.8% above what analysts expected.

Estimated report: Nov 12, 2026, in 11 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Actuate Therapeutics, Inc. Common stock

Smart money at a glance

What do analysts expect?

Questions about ACTU filings

Questions about ACTU filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 4.8% above what analysts expected.

Estimated report: Nov 12, 2026, in 11 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Actuate Therapeutics, Inc. Common stock

Overview

Questions about ACTU filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Actuate Therapeutics, Inc. Common stock

Overview

Questions about ACTU filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.